How to Choose RNA Fusion Reference Standards for Your Assay

Choosing RNA fusion reference standards starts with the question your assay needs to answer. A material for checking fusion detection after RNA extraction serves a different purpose from a control that also passes through extraction. The specific transcript, material format, target abundance, and supporting documentation all affect whether the standard fits your work.

This guide helps assay developers and molecular laboratories compare these factors before selecting reference materials for development, analytical validation, or routine quality control.

Key Takeaways

• Match the fusion partners and transcript junction to the targets your assay is designed to detect.

• Choose a material that enters the workflow early enough to evaluate the steps of interest.

• Review target-specific copy numbers separately from total RNA concentration.

• Confirm suitability for your assay chemistry and analysis pipeline.

• Request the current lot documentation before defining expected results or ordering quantities.

Start With the Intended Use of the Control

RNA fusion reference standards contain specified fusion transcripts that can support assay development and performance monitoring. Their usefulness depends on what you want to evaluate: detection of a particular junction, performance across several targets, extraction, or detection at lower transcript abundance.

Write down the intended use before comparing products. For example, an extraction study needs a material processed through extraction, while an investigation of downstream detection can begin with purified RNA. A sensitivity study also needs information about target abundance and the experimental conditions under which it is measured.

When reviewing fusion reference standards, compare the required transcript, format, and characterization data alongside the product name. These details determine which experimental question the material can help answer.

Match the Specific Fusion Transcript

A gene name alone is insufficient for selecting a fusion-positive control. Review the two fusion partners and the exon junction represented in the material.

For example, EML4 exon 13–ALK exon 20 and EML4 exon 6–ALK exon 20 are different transcript junctions. A reference material containing one junction does not automatically provide a positive control for a junction-specific assay targeting the other.

Build a coverage checklist that includes:

• The fusion partner pair.

• The exon junction or junction sequence.

• The transcript accession and version, where available.

• The region targeted by your primers or enrichment probes.

• The fusion call expected from your reporting software.

Resolve annotation differences before purchase. If the supplier and your assay use different exon numbering, request the transcript reference or sequence needed to establish whether they describe the same target.

For a multiplex panel, compare the actual transcript list with the assay design. A larger control panel is useful only to the extent that its targets address your evaluation needs. A published RNA fusion panel validation, for example, could not detect a fusion in its reference material because that gene was outside the assay design.

Choose a Format That Covers the Required Workflow Steps

Material format determines where the control enters the workflow. Purified RNA, cell pellets, and formalin-fixed paraffin-embedded (FFPE) materials offer different starting points.

Purified RNA does not evaluate the extraction steps that occurred before it entered the assay. Likewise, RNA already extracted from FFPE does not test your laboratory’s FFPE extraction process.

If your objective includes FFPE extraction, select an appropriate FFPE reference material and process it through the relevant preparation and extraction steps. Manufacturer studies demonstrate the use of FFPE fusion materials for evaluating extraction as part of an RNA fusion workflow.

Also check how the material was constructed. Cell-derived RNA and synthetic RNA constructs differ in their design and background. For synthetic materials, ask about the sequence extending around the fusion junction and whether the material is supplied alone or in background RNA. Evaluate these features against your method rather than choosing solely by the manufacturing label.

Check Compatibility With the Assay Chemistry

“RNA fusion detection” encompasses different methods. RT-qPCR and RT-dPCR assays require an appropriate target for their primers and probes. Targeted RNA NGS also depends on enrichment design and the fusion analysis pipeline.

For PCR-based testing, confirm that the material includes the sequence needed for the intended amplification and detection. For NGS, review the relevant amplicon or capture regions, library preparation requirements, and expected fusion annotation.

Ask for compatibility evidence that identifies the actual assay or workflow tested. A general statement that a control supports NGS cannot establish its performance with every panel and software combination.

Keep the nucleic acid type aligned with the measurement. An RNA control challenges RNA-based detection; it does not automatically establish performance for a DNA rearrangement assay. Some engineered RNA fusion materials contain the fusion transcript without the corresponding translocation at the DNA level.

Review Target Abundance and RNA Quality Separately

Distinguish RNA Mass From Fusion Copy Number

Total RNA concentration and fusion transcript abundance answer different questions. A concentration in ng/µL describes RNA mass per volume. A target-specific value in copies/ng describes the measured copies of that transcript relative to RNA mass.

Check the unit and denominator before comparing materials:

In a multiplex material, review abundance for each transcript. Targets in the same vial need not have equal copy numbers; individual fusion abundance can differ substantially.

Review How the Values Were Assigned

For RNA measurements, reverse transcription can introduce uncertainty and bias. The enzyme, priming strategy, RNA input, and subsequent processing are relevant to interpreting RT-dPCR results.

Request the characterization method alongside the assigned values. Establish expectations under your own assay conditions rather than assuming that a different reverse transcription and PCR system will reproduce the supplier’s result exactly.

NGS fusion-supporting reads are also distinct from absolute transcript copy numbers. A validation study comparing these measurements found target-dependent differences in their relationship. Use the read metrics defined for your assay when assessing sequencing results.

Assess Quality Against the Intended Method

For FFPE-derived RNA, ask for relevant quality information in addition to concentration. DV200, for example, expresses the percentage of RNA fragments longer than 200 nucleotides. Its acceptance criteria should follow the specific library preparation or assay requirements.

Avoid applying a quality threshold from one assay to every RNA fusion workflow. The useful question is whether the material’s documented quality fits the method and evaluation you plan to perform.

Select the Coverage and Abundance Needed for the Study

A single-fusion control can address a focused target investigation. A multiplex control can help evaluate several specified transcripts in the same workflow. When considering multiplex RNA fusion controls, review the individual junctions and quantitative information needed for your panel.

For analytical sensitivity work, look for documented target abundance appropriate to the planned study. Lower-abundance RNA fusion materials are available specifically for limit-of-detection investigations and routine quality control. The material supports the experiment; it does not establish your assay’s detection limit by itself.

Define the role of negative materials as well as positive controls. In PCR experiments, background RNA, no-template controls, and no-reverse-transcription controls answer different questions. Select them according to the assay and the potential source of an unexpected signal.

For clinical assay validation, reference materials should form part of the planned evidence alongside appropriate characterized clinical specimens. AMP/CAP guidance includes both types of material in the validation process.

Request the Documentation Before Ordering

Use this practical checklist to make the purchase decision reviewable:

Share your assay design and evaluation objective with the supplier when requesting these documents. Include whether extraction is part of the study, the required junctions, the detection method, and the target abundance range of interest.

Conclusion

Choose RNA fusion reference standards by matching the material to the experiment: the specific transcript, the workflow entry point, the assay chemistry, and the quantitative information you need. Confirm those choices with current product and lot documentation. This gives your team a clear basis for selecting controls and interpreting their results.

Discuss Your RNA Fusion Control Requirements

Share your fusion targets, assay method, required material format, and evaluation objective with CB-Gene. Contact our team to discuss available options and request supporting documentation.

Frequently Asked Questions

What Information Is Needed to Choose an RNA Fusion Reference Standard?

Start with the fusion partners and junction, assay method, and workflow steps to be evaluated. Then review target abundance, RNA quality, and the current product and lot documentation.

Can Purified RNA Be Used to Evaluate FFPE RNA Extraction?

Purified RNA starts after extraction and therefore does not evaluate your extraction procedure. To include that stage, choose a suitable FFPE reference material and process it through the intended workflow.

Does an ALK-Positive Material Cover Every ALK Fusion Assay?

Coverage depends on the specific transcript and assay design. Check the fusion partner and exon junction, together with the sequence targeted by your method.

Why Might My RT-dPCR Result Differ From the Assigned Copy Number?

Reverse transcription and PCR conditions can affect RNA quantification. Compare the characterization method, measurement units, and input conditions before interpreting a difference.

Is a Multiplex RNA Fusion Control Sufficient for Complete Assay Validation?

A multiplex control provides specified positive targets. Complete validation requires a study designed around the assay’s intended use and performance characteristics, with appropriate controls and characterized specimens.